ALNY vs BBIO
ALNY: Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions. BBIO: BridgeBio is a portfolio-based biotech firm focused on translating genetic science into precision therapies for patients with severe genetic disorders.
Side-by-side fundamentals
| Metric | ALNY | BBIO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $224.53 | $65.04 | |
| Market cap | $30.0B | $12.7B | |
| P/E as of 2026-10-08 | 38.21 | n/a | |
| Net margin FY2025, SEC XBRL | +8.4% | -146.0% | ALNY higher |
| Operating margin FY2025, SEC XBRL | +13.5% | -104.2% | ALNY higher |
| ROE FY2025, SEC XBRL | +39.8% | n/a | |
| ROA FY2025, SEC XBRL | +6.3% | -78.3% | ALNY higher |
| Debt / equity as of 2026-09-03 | 2.02 | 8.27 | ALNY lower |
| Revenue growth (YoY) as of 2026-09-03 | +95.1% | +355.2% | BBIO higher |
| Revenue CAGR (3y) SEC XBRL | +53.0% | +86.3% | BBIO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.80 | 1.06 | |
| 1-year return as of 2026-10-08 close | -50.2% | +17.6% | BBIO higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.